Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Use of 31P MRS to Assess Brain NAD+ in Healthy Collegiate Football Players (TRMC-004)

This study is currently recruiting participants. (see Contacts and Locations)
Verified March 2017 by Mayo Clinic
Sponsor:
Collaborators:
University of Minnesota - Clinical and Translational Science Institute
Thorne Research Inc.
Information provided by (Responsible Party):
Brent A. Bauer, Mayo Clinic
ClinicalTrials.gov Identifier:
NCT02721537
First received: March 24, 2016
Last updated: March 23, 2017
Last verified: March 2017

March 24, 2016
March 23, 2017
September 2016
March 2017   (Final data collection date for primary outcome measure)
Change in brain NAD+ levels [ Time Frame: baseline, day 84 ]
Same as current
Complete list of historical versions of study NCT02721537 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Use of 31P MRS to Assess Brain NAD+ in Healthy Collegiate Football Players
Use of 31P MRS to Assess Brain NAD+ in Healthy Collegiate Football Players and a Comparison of the Effect of Nicotinamide Riboside Supplementation on Brain NAD+ Levels
Can nicotinamide riboside (750 mg/day for 12 weeks) affect the levels of NAD+ in the brain as measured by 31P MRS?
Healthy collegiate football players will take Nicotinamide Riboside (NR) or placebo twice daily for 84 days. Pre- and post-intervention evaluations include physical assessment, blood tests for safety and toxicity monitoring, blood tests for biomarkers, neurologic testing, quality of life questionnaires, and the 31P MRI exam.
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Investigator
Primary Purpose: Other
Concussion, Mild
  • Dietary Supplement: Nicotinamide Riboside
    Three capsules, twice per day for 84 days
    Other Name: Niagen
  • Other: Matching placebo
    Three matching capsules, twice per day for 84 days
  • Active Comparator: Arm A: Healthy Football Players
    Healthy collegiate football players will take active Nicotinamide Riboside
    Intervention: Dietary Supplement: Nicotinamide Riboside
  • Placebo Comparator: Arm B: Healthy Football Players
    Healthy collegiate football players will take a matching placebo
    Intervention: Other: Matching placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
48
September 2017
March 2017   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Adult male collegiate football players
  • History of at least 1 year playing experience at the collegiate level
  • Body mass index (estimated based on height and weight) from 23 to 37
  • Willing to provide informed consent, ingest test substance, and provide blood specimens
  • Willing to comply with study instructions and maintain current level of physical activity throughout the study

Exclusion Criteria:

  • History of loss of consciousness of more than 5 minutes
  • Contraindications to Magnetic Resonance Imaging (MRI), such as implanted medical devices, metal objects, or pacemakers
  • History of epilepsy
  • History of more than 3 concussions
  • History of headache preceding a concussion
  • History of depression preceding a concussion
  • History of developmental delays or Attention Deficit Hyperactivity Disorder (ADHD)
  • History of post-traumatic seizures
  • History of complex spine and/or skull trauma
Sexes Eligible for Study: Male
18 Years and older   (Adult, Senior)
Yes
Contact: Karrie M. Fursa 507-266-2218 fursa.karrie@mayo.edu
Contact: Sharon F. Kaufman, M.S. 507-283-1605 kaufman.sharon@mayo.edu
United States
 
 
NCT02721537
15-006870
No
Not Provided
Yes
Not Provided
Brent A. Bauer, Mayo Clinic
Mayo Clinic
  • University of Minnesota - Clinical and Translational Science Institute
  • Thorne Research Inc.
Principal Investigator: Brent A. Bauer, M.D. Mayo Clinic in Rochester, MN
Mayo Clinic
March 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP